
    
      The screening period = up to 4 weeks prior to SAR3419 administration

      The treatment period = from the day of first administration of SAR3419 until the
      End-Of-Treatment visit. All patients will receive SAR3419 until evidence of disease
      progression, unacceptable toxicity or other reasons for therapy discontinuation - After
      therapy discontinuation all patients will enter a safety follow-up period of 42 days starting
      from the day of administration of the last dose of SAR3419 and ending with the End Of
      Treatment visit.

      All patients, regardless whether they have progressed or not, will be followed until death or
      end of study to evaluate survival for at least 18 months.
    
  